

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 19th day of April 2002.

By

Evelyn Sabatino
(Signature of person mailing)
Evelyn Sabatino

(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anton Fliri et al.

APPLICATION NO.: 09/965,563

: Examiner: Unassigned

FILING DATE: September 27, 2001

: Group Art Unit: Unassigned

TITLE: SUBSTITUTED BICYCLIC
DERIVATIVES FOR TREATING
CENTRAL NERVOUS SYSTEM
DISORDERS

RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).). **Copies of the references are found in the file of parent application 09/300,262.**

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: 4/19/02

Respectfully submitted,

E. Victor Donahue
E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-2739

INFORMATION DISCLOSURE CITATION (On several sheets if necessary)								ATTY. DOCKET NO. PC9869B				SERIAL NO. 09/965,563			
APPLICANT Anton Fliri et al.															
FILING DATE September 27, 2001												GROUP			
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	5	8	5	2	0	3	1	12/22/98	Kishor A. Desai et al.						
<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <p>COPY OF PAPERS ORIGINALLY FILED</p> <hr style="width: 150px; margin: 10px auto;"/> </div> <div style="text-align: center;"> <p>RECEIVED</p> <p>MAY 02 2002</p> <p>TECH CENTER 1600/2900</p> </div> </div>															
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	WO	95/	3	4	5	5	5	12/21/95	PCT						
	WO	96/	0	4	2	5	0	02/15/96	PCT						
EP	0	7	4	5	5	9	8	12/04/96	EPO						
	WO	98/	0	8	8	3	5	03/05/98	PCT						
	WO	99/	0	9	0	2	5	2/25/99	PCT						
	WO	96/	1	0	5	7	1	4/11/96	PCT						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
Hadley, M.S., "D4 Receptors and Their Antagonists" Medicinal Research Reviews, Vol. 16, no. 6, pp. 507-526, (1996)															
EXAMINER															
DATE CONSIDERED															
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE